Trial Profile
A Trial of Atovaquone (Mepron) Combined With Conventional Chemotherapy for de Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults (ATACC AML)
Status:
Active, no longer recruiting
Phase of Trial:
Phase 0
Latest Information Update: 24 Jan 2022
Price :
$35
*
At a glance
- Drugs Atovaquone (Primary) ; Cytarabine (Primary) ; Daunorubicin (Primary) ; Etoposide (Primary) ; Gemtuzumab ozogamicin (Primary) ; Cytarabine/daunorubicin
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Pharmacokinetics
- Acronyms ATACC AML
- 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 10 Oct 2020 Planned End Date changed from 1 Jan 2021 to 31 Oct 2025.
- 10 Oct 2020 Status changed from recruiting to active, no longer recruiting.